EUCAST technical note on posaconazole

被引：14

作者：

Arendrup, M. C. ^{[1
]}

Cuenca-Estrella, M. ^{[2
]}

Donnelly, J. P. ^{[3
,4
]}

Hope, W. ^{[5
]}

Lass-Floerl, C. ^{[6
]}

Rodriguez-Tudela, J-L ^{[2
]}

机构：

[1] Statens Serum Inst, Dept Microbiol Surveillance & Res, Unit Mycol, DK-2300 Copenhagen, Denmark

[2] Inst Salud Carlos III, Mycol Reference Lab, Natl Ctr Microbiol, Majadahonda, Spain

[3] Radboud Univ Nijmegen, Dept Haematol, Med Ctr, Nijmegen, Netherlands

[4] Radboud Univ Nijmegen, Nijmegen Univ Ctr Infect Dis, Nijmegen, Netherlands

[5] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Univ Hosp S Manchester NHS Fdn Trust, Manchester, Lancs, England

[6] Innsbruck Med Univ, Div Hyg & Microbiol, Innsbruck, Austria

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2011年 / 17卷 / 11期

关键词：

breakpoints; Candida; EUCAST Technical Note; Posaconazole; susceptibility testing; AZOLE-REFRACTORY OROPHARYNGEAL; ESOPHAGEAL CANDIDIASIS; HIV-INFECTION;

D O I：

10.1111/j.1469-0691.2011.03646.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for posaconazole for Candida spp. This Technical Note is based on the EUCAST posaconazole rationale document (available on the EUCAST website: http://www.eucast.org). Species-specific breakpoints for C. albicans, C. parapsilosis and C. tropicalis are S: MIC <= 0.06 mg/L, R: MIC >0.06 mg/L. There are insufficient data to set breakpoints for C. glabrata and C. krusei as well as non-species-related breakpoints. The breakpoints are based upon pharmacokinetic data, epidemiological cut-off values and clinical experience. Breakpoints will be reviewed regularly.

引用

页码：E16 / E17

页数：2

共 6 条

[1] Posaconazole plasma concentrations in juvenile patients with invasive fungal infection [J].

Krishna, Gopal ;

Sansone-Parsons, Angela ;

Martinho, Monika ;

Kantesaria, Lhavna ;

Pedicone, Lisa .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (03) :812-818

[2] Effect of Varying Amounts of a Liquid Nutritional Supplement on the Pharmacokinetics of Posaconazole in Healthy Volunteers [J].

Krishna, Gopal ;

Ma, Lei ;

Vickery, Donna ;

Yu, Xin ;

Wu, Irene ;

Power, Edward ;

Beresford, Eric ;

Komjathy, Steven .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) :4749-4752

[3] Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers [J].

Krishna, Gopal ;

Moton, Allen ;

Ma, Lei ;

Medlock, Matthew M. ;

McLeod, James .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :958-966

[4] Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection [J].

Skiest, Daniel J. ;

Vazquez, Jose A. ;

Anstead, Gregory M. ;

Graybill, John R. ;

Reynes, Jacques ;

Ward, Douglas ;

Hare, Roberta ;

Boparai, Navdeep ;

Isaacs, Randi .

CLINICAL INFECTIOUS DISEASES, 2007, 44 (04) :607-614

[5] Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection [J].

Vazquez, J. A. ;

Skiest, D. J. ;

Tissot-Dupont, H. ;

Lennox, J. L. ;

Boparai, N. ;

Isaacs, R. .

HIV CLINICAL TRIALS, 2007, 8 (02) :86-97

[6] A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS [J].

Vazquez, JA ;

Skiest, DJ ;

Nieto, L ;

Northland, R ;

Sanne, I ;

Gogate, J ;

Greaves, W ;

Isaacs, R .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (08) :1179-1186

← 1 →